What is a "food-derived bioactive technology" and a "functional food"?
It is becoming increasingly accepted by the scientific community that there are links between specific food groups and their capacity to help reduce the risk of certain diseases. For example, some compounds specifically found in broccoli have been shown to reduce the risk of some cancers. Consuming the actual food may be insufficient to maximise the health benefit due to a number of factors including: the quantity of the food that would need to be consumed; the frequency with which it would need to be consumed; and the way in which the food is prepared prior to consumption.

These health-promoting compounds can be extracted from the food source (called a food-derived bioactive technology) and reintroduced into consumer-friendly lifestyle products which are proven to maintain health (a functional food). Therefore, instead of eating four large servings of broccoli per week, the same benefit may be technically delivered via a 250ml orange juice drink containing the bioactive if consumed once per week.

How is Provexis differentiated from other companies in the market?
Provexis is an evidence-based business which means that we only develop food-derived bioactive technologies and functional food products that have been scientifically proven to deliver a health benefit. This is a different approach from those that promote functional food products in a more generic way with less scientific evidence. We believe that functional food products with strong scientific proof carrying health claims and endorsements will endure and prosper as this rapidly growing market matures.

Provexis is also differentiated with regard to our speed-to-market credentials and the fact that we can create shareholder value via a combination of technology licensing and own brand development.

What food-derived bioactive technologies are being developed by Provexis?
Provexis has developed Fruitflow, a patented extract from tomato that has been proven to inhibit blood platelet aggregation, thereby reducing the risk of thrombosis. A thrombosis is an aberrant blood clot that can lead to heart attack and stroke. Provexis has integrated Fruitflow into a fruit juice beverage called Sirco. When launched - initially in the United Kingdom - it will be the first functional food carrying the claim Helps maintain a healthy heart and benefit circulation with a measurable benefit within hours of consumption.

Provexis is developing a proprietary extract from a special breed of broccoli (non-GMO) which is enriched in compounds known to reduce the risk of specific cancers. Provexis intends to use this food-derived bioactive to underpin a new range of functional beverages with scientifically proven protective properties.

In addition, Provexis is developing a patented extract from plantain with a view to developing a novel medical food for the dietary management of Inflammatory Bowel Disease, specifically Crohns Disease in the first instance.

PROVEXIS PLC
("Provexis" or the "Company")

Provexis and HEART UK enter product endorsement agreement

Provexis, the nutraceutical company that develops scientifically proven
functional and medical foods, is delighted to announce their entry into an
initial three-year agreement with the registered heart health charity, HEART UK,
which will see formal approval of the Company's lead product, the fruit juice
drink Sirco(TM). In addition the two organisations will collaborate in research
and educational activities designed to increase awareness of family heart
health issues amongst the public.

Sirco(TM), carrying the HEART UK logo, will initially be available in two
flavours and the Company is currently planning, with major retailers, a national
UK launch. The Sirco(TM) packaging will show that the product "Helps to maintain
a healthy heart and benefits the circulation."

Sirco(TM) contains the patented natural fruit extract called Fruitflow(TM).
Fruitflow(TM) was discovered at the Rowett Research Institute in 1998 and since
2000 has been developed and clinically tested in human trials by Provexis.

Fruitflow(TM) contains a range of tasteless tomato-derived natural compounds
which have been proven to inhibit platelet aggregation, a part of the blood-
clotting process which can cause heart attack and stroke.

According to the British Heart Foundation, heart and circulatory disease is the
UK's biggest killer.

Sirco(TM) is being launched into a new, emerging category in the UK:
"heart-healthy" functional juices. This category first emerged in the US in the
last two years, with rapid growth to 2004 sales of $100.1m, according to
Information Resources Inc. data.

Dr Stephen Franklin, Chief Executive Officer of Provexis, said: "The approval
granted by HEART UK is excellent news, and we look forward to working together
in a proactive manner to promote heart health. Our strategy is to differentiate
ourselves in the functional food industry by investing in R&D and developing
products that taste great, deliver proven health benefits, and carry credible
health claims supported by strong scientific proof."

Michael Livingston, the Director of HEART UK said: "The Charity is delighted
to be embarking on a long-term partnership with Provexis plc to help people take
proactive steps to reduce their risk of heart disease."


Ends


For further information please contact:

Provexis plc
Dr Stephen Franklin, CEO 07710 348 774

Bell Pottinger Corporate and Financial
Ann-Marie Wilkinson/Emma Kent 020 7861 3232


Notes to Editors

Provexis develops scientifically proven functional and medical foods. Functional
foods are foods such as Benecol and Flora pro.activ that contain physiologically
active food components and provide health benefits beyond basic nutrition. In
June 2005 the Company joined AIM via a reverse takeover by Nutrinnovator.
Nutrinnovator came into operation in February 2003 and launched the Altu
nutrition bar, floated on AIM in June 2004 and brings with it a technology
pipeline as well as marketing, selling and business development skills.

Provexis was formed in December 1999 by the life-science subsidiary of the
venture-management company, ANGLE plc. In January 2000, Provexis entered into a
new technology option agreement with Rowett Research Services Ltd. (RRS), the
commercial subsidiary of the Aberdeen based Rowett Institute, and this option
was exercised in November 2001. Provexis' agreements with RRS have provided it
with the intellectual property rights pertaining to its lead product, Fruitflow.
Provexis continues to have strong links with the Rowett Institute, which
provides the company with R&D facilities, human trials and, potentially, new
technologies.

HEART UK is a national charity of patients and their families, supporting
research and helping to increase awareness and understanding of the importance
of Heart Health and how to maintain a healthy cardiovascular system. HEART UK
works with patients and their families and combines the rich skills of research
scientists, the caring knowledgeable attention of doctors, nurses and
dietitians, in order to support all those at risk of cardiovascular disease.

Product Overview

The company has an initial pipeline of four products in development:

* Fruitflow(TM) - a proprietary tomato extract proven to reduce platelet
aggregation which reduces the risk of thrombosis, a major cause of heart
attack and stroke
* Plantain extract - for digestive health and management of inflammatory
bowel disease
* Superbroccoli - broccoli based extract for the reduction of risk of
specific cancers
* Omega III oil technology - for heart-health and cognitive benefits

The Fruitflow(TM) intellectual property rights are broad and well protected, and
the product has been granted patent in Europe and Australia, and has a patent
grant pending in the US.

Hi All

Thought I would start this thread to get the ball rolling on this company, if you are in let us know what you think, if you are thinking of getting in tell us why, and if you think its a dog a would'nt touch it with a barge pole, why not?

Look forward to hearing your veiws, good or bad.

Regards Doh

Hi Doh, ive just started looking in to this one, ,shares mag featured it a few weeks back,, looks interesting, they have a website with lots of info , i'll be back...Cheers JB...

You may have already looked at this , but just in case it's www.provexis.com, check it out..

i used to have angle because of pxs. bought pxs a few weeks ago after seeing it getting a mention in shares mag. i think the agm statement has kicked this one into life. buy now and wait till january.

Provexis plc

AGM STATEMENT


Dawson Buck, Chairman of Provexis plc, will make the following statement at
today's Annual General Meeting ('AGM'):

'Provexis plc was admitted to trading on AIM exactly two months ago. This was
the coming together of two businesses, Provexis Limited and Nutrinnovator
Holdings plc, with the shared vision of creating a company which is now uniquely
differentiated in the functional food market.

Subsequently, I am delighted to report that the integration has gone extremely
well and the new team has a clear, shared energy and commitment to the future
success of Provexis plc.

Our lead product, SircoTM, is a fruit juice drink that contains a patented
bioactive extract from tomatoes (called FruitflowTM). It has been proven in
human trials to inhibit blood platelet aggregation and thereby reduce the risk
of thrombosis, the primary cause of heart attack and stroke. SircoTM, which
carries a health claim, is uniquely positioned in the heart health category due
to its function and the immediacy of the benefit.

Earlier this month we announced a three-year agreement with the registered heart
health charity, H-E-A-R-T UK, for SircoTM, which provides us with formal
approval and endorsement of the product.

Due to the high level of interest from a number of the major UK supermarkets and
other key high street retailers, we are now planning a much larger distribution
base at launch, supported by a nationwide marketing campaign in early 2006.

Both the supermarkets and the retailers have indicated that maximum impact will
be made by a launch in the post-Christmas period, when health and wellbeing is
at its highest on the consumer's personal agenda. We will therefore be launching
SircoTM in January 2006.

Whilst the current focus is working towards the launch of SircoTM the R&D
pipeline, in conjunction with our technology partners, continues to progress.
This includes the functional fruit juice beverage which will contain a
proprietary extract from broccoli proven to reduce the risk of specific cancers
and the medical food for the dietary management of Crohn's Disease. The Board
continues to monitor the Altu food bar and is considering its future strategy in
relation to this product.

Provexis plc has made a positive start since admission to AIM in June and the
Company is now gearing up to the launch of SircoTM in January 2006. I look
forward to reporting further progress in due course.'

Cheers bosley..

Looks wildly speculative to me, but if the alternative is to eat pounds of tomatoes and broccoli every day....

Exactly, partridge you would need to eat 10 bushes of broccoli and 487 tomatos, twice a day , so if your not interested in the shares, at least drink the product !!

jimmy, when angle spoke about the product there was mention of the airlines being interested, as the tomato extract works similar to asprin in thinning the blood so it would be useful in combatting deep vein thrombosis. i haven't seen anything about that since, but it certainly makes sense for the long haul airlines to offer such a drink.
partridge, yes, very speculative and pxs is pretty much a one horse company at the moment, so if sirco doesn't happen it will collapse on it's arse. but, if it does happen............

bos i know ,,they are going for the airports as well ,,have you been on the website? i'm not in as yet ,, but i'm lurking..

Hi All

Glad there is some interest out there, I have been in this for a couple of days now, dipped a toe at 7p and stuck both legs in 7.5p , I must admit I wasn't expecting it to rise quite so quickly. Its not to surprising though when you look at the product.

partridge: I wouldn't have said it was wildly speculative, I think the fact they have independent clinical trials to back up their claims and the fact they have the backing of a heart charity may just promote this to speculative. The only reason I think you could possible keep this in the speculative category is because the product is not on the shelves yet.

bosley: excellent advise, however I think I might wait a bit longer I want to see how they intend to spend the 2.5mil advertising budget.
jimmy b: Don't lurk to long, hope to see you on board soon, however if you turn up something you don't like feel free to share it with us.

Best of luck to all,
Regards Doh

doh. that's probably the best thing about pxs , that it's gone past trial stage and is a product waiting to be launched. i got in at 5.5p but, like yourself, was surprised at the sudden movement. if pxs is successful then agl would also be a good buy as it still owns 24/25%.
jimmyb, i didn't think about the airports but it makes sense. (take a butchers at icu, jam tomorrow but could be nice)

pxs having a good day today , as is icu . good feature in shares mag yesterday about the boss of icu. it's about time shares mag had pxs as a play of the week. they have already done a couple of features on it.

A good day indeed bosley. Many more please. LOL

another kick up for pxs. again this wasnt flagged up by the news ticker!!

"Provexis PLC
12 September 2005


PROVEXIS PLC
('Provexis' or the 'Company')

COLLABORATION AGREEMENT FOR CROHN'S DISEASE TECHNOLOGY

Exercise of right to assign intellectual property from University of Liverpool


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, is delighted to announce that it has entered into
a collaboration agreement with a leading clinical nutrition company ('the
Company').

Provexis is currently developing a proprietary bioactive extract from the
Plantain (part of the banana family) which is designed to extend remission in
patients suffering from Inflammatory Bowel Disease (IBD). IBD has two forms,
Crohn's Disease and Ulcerative Colitis, both are chronic inflammatory diseases
of the digestive tract which, combined, affect approximately 1 in 400 in the
western world countries.

Under the terms of the collaboration agreement, Provexis and the Company will
develop a medical food product incorporating this bioactive extract. It is
intended that the food product will enter clinical trials in 2006 on patients
suffering from Crohn's disease. Crohn's Disease is currently incurable with the
primary goals of treatment being control of the inflammation, the relief of
symptoms, addressing nutritional deficiencies and the extension of remission
time.

The Company will be responsible for the formulation, manufacture and packaging
of the medical food product to be used in the full clinical trial and will have
the option of securing an exclusive negotiation period after the trial. The
negotiation period would give the Company the rights to be the first company to
pursue the manufacturing and distribution rights for the product. However,
Provexis is not obliged to enter into an agreement with the Company for these
rights and furthermore, all intellectual property, including the industrial
formulation of the medical food product, is wholly-owned by Provexis.

In addition, following successful pre-clinical studies on this medical food
treatment by the University of Liverpool and Provexis, Provexis has exercised
its right to the assignment of the intellectual property from the University of
Liverpool to a new Provexis subsidiary in which the University will be a
minority shareholder.

The specific components in Plantain with this therapeutic potential were
discovered by Professor Jon Rhodes, based in the Department of Medicine at the
University of Liverpool and an Honorary Consultant Gastroenterologist at the
Royal Liverpool University Hospital.

Dr Stephen Franklin, CEO of Provexis, commented: 'This is another significant
milestone in the development of Provexis. This collaboration is an important
validation of the strength of the Provexis technology pipeline.'


Ends


For further information please contact:

Provexis plc
Dr Stephen Franklin, CEO 07710 348 774

Bell Pottinger Corporate and Financial
Ann-Marie Wilkinson/Emma Kent 020 7861 3232


Notes to Editors

Provexis develops scientifically proven functional and medical foods. Functional
foods are foods such as Benecol and Flora pro.activ that contain physiologically
active food components and provide health benefits beyond basic nutrition.
Medical foods are administered to patients by a physician for the dietary
management of specific diseases.

In June 2005 the Company joined AIM via a reverse takeover by Nutrinnovator.
Nutrinnovator brings with it a technology pipeline as well as marketing, selling
and business development skills.

Provexis was formed in December 1999 by the life-science subsidiary of the
venture-management company, ANGLE plc. In January 2000, Provexis entered into a
new technology option agreement with Rowett Research Services Ltd. (RRS), the
commercial subsidiary of the Aberdeen based Rowett Institute, and this option
was exercised in November 2001. Provexis' agreements with RRS have provided it
with the intellectual property rights pertaining to its lead product, Fruitflow.
Provexis continues to have strong links with the Rowett Institute, which
provides the company with R&D facilities, human trials and, potentially, new
technologies.


IBD - Technical

Researchers at the University of Liverpool have recognised that IBD may
represent an altered response to normal intestinal microbes In particular, they
believe there is a possibility that apparently non-pathogenic 'harmless '
bacteria can cause inflammation if they penetrate the intestinal mucus and
associate themselves with the lining cells of the intestine.

The researchers have characterised the adherence of Inflammatory Bowel Disease
related bacteria to carbohydrate structures on the lining of the intestine and
found that the adhesion of such bacteria to cell surfaces can be blocked by
some, but not all, complex carbohydrates. In particular, they found that
specific types of soluble fibre, extracted from Plantain, were particularly
effective for preventing bacterial adhesion and accordingly may have efficacy
for preventing or treating IBD. They believe that the soluble fibres may either
mimic or compete with bacterial receptors, thus preventing bacterial recruitment
and subsequent inflammation.

This discovery has led Provexis to believe that a Plantain--based formulation
(as developed by chemists at Provexis and tested at the University of Liverpool)
could underpin a new medical food treatment for extending remission time in
patients with IBD.

The medical food product is anticipated to enter a two-site clinical trial on
patients with Crohn's Disease in Summer 2006.



This information is provided by RNS
The company news service from the London Stock Exchange

just seen this on the psg thread. hope sd doesn't mind. taken from a post from feb 2005.

"Peter Brabeck, head of Nestle and one of the most influential
people in the food industry, was interviewed in yesterdays Financial
Times:-

"It is my conviction that the next value creation, and it will be huge,
is going to be nutritional aspects. That is what allows you to ask 40%
more for your products".

The article continued that foods with medical benefits, otherwise known
as functional foods or nutraceuticals are expected to be the big source of
growth for the next 15 to 20 years. "

all gone a bit quiet and the sp has dropped a touch. not really much going to happen until january , i think.

looks like pxs have decided to ditch altu. makes sense as it was loss making.

Provexis PLC
05 October 2005


PROVEXIS PLC

Disposal of Altu

Provexis plc ('Provexis' or the 'Company') AIM: PXS.L, announces the sale of its
Altu food business to Go Lower Limited for a cash consideration of 75,000 which
will be used for working capital purposes.

As stated at the AGM, the Board has been closely monitoring the performance of
Altu. The brand has recently extended its distribution, via a new pack format,
in two multiple grocers, and continues to enjoy national distribution in High
Street and Major Multiple Grocers. However, following a strategic review, the
Board has concluded that, in order to focus on the core activity of functional
foods, a disposal of the Altu business is in the best interests of the Company
and shareholders.

For the year ended 31 March 2005, the Altu business was loss-making, after
direct overheads on turnover of 298,000 and in the year to date has continued
to be loss-making. The disposal therefore will have a cash positive effect on
Provexis' business going forward.

Commenting, Dr Stephen Franklin, CEO said:

'Provexis will now be able to focus its resources and management time on its
core business: the development of novel, patented, food bioactives with
scientifically-proven health benefits. These will be commercialised via a
combination of licensing and own-brand functional foods.'

3 November 2005

PROVEXIS PLC
('Provexis' or the 'Company')


US PATENT AWARDED COVERING FRUITFLOW TECHNOLOGY


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces that it has received a patent grant from
the United States Patent Office covering its FruitflowTM technology.

The FruitflowTM technology covered by this patent was discovered at the Rowett
Research Institute in 1998 and has been developed and clinically tested by
Provexis since 2000. FruitflowTM contains a bioactive extract from tomatoes
which has been proven in human trials to inhibit blood platelet aggregation and
thereby reduce the risk of thrombosis, a primary cause of heart attack and
stroke. The technology already has patent protection in Europe, granted in July
2003, and in Australia, granted in August 2004. It is also anticipated that
patent protection will be granted in Japan, Mexico and Canada in the near
future.

Provexis will be launching the FruitflowTM technology in its lead product, the
fruit juice drink SircoTM, in January 2006 in the UK. SircoTM has been approved
by HEART UK and will carry the claim 'helps to maintain a healthy heart and
benefits the circulation'. SircoTM is differentiated from existing cholesterol
management products in that the benefit is associated with blood thinning and is
effective from the first serving. The launch will be targeting a new, emerging
category in the functional food market in the UK: heart-healthy functional
juices. The market for heart-healthy foods worldwide is expected to reach US$4.6
billion of sales by the end of 2005.

Dr Stephen Franklin, Chief Executive Officer of Provexis, said: 'We are
delighted to have been granted the US patent for our FruitflowTM technology. We
now have patent protection in our two largest target markets, the United States
and Europe. This is a critical development in terms of our licensing ambitions
and it means that we can start to make significant in-roads into the US
functional food market, which is expected to reach US$34 billion of sales by
2010.'


this is fantastic news for pxs!!!

wheres this one going fruit flow released to market january ,going to get some haVe a taste .they haVe had 2 jumps off 5p will they brake this range to find 10p and aboVe ,they were 60p without there patent or product tomarket .i hold 50k shares at 6.4p ,thinking to double up on next dip haVe a good feeling about these ,

more news today.

Provexis PLC
07 November 2005



7 November 2005



PROVEXIS PLC
('Provexis' or the 'Company')


Provexis plc is awarded Research Grant for Crohn's Disease Technology from North
West Development Agency


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, is delighted to announce that it has been awarded
a research grant for its Crohn's disease technology from the North West
Development Agency. The grant is for 180,000 and will assist the funding of the
Company's development of its novel, medical food for the treatment and dietary
management of inflammatory bowel disease (IBD).

Provexis is currently developing a proprietary bioactive extract from plantain
(part of the banana family) which is designed to extend remission in patients
suffering from IBD, which exists in two forms - Crohn's disease and ulcerative
colitis. Collectively, both forms of the disease affect approximately 1 in 400
in the western world. According to Decision Resources (2004), for Crohn's
disease alone, the therapeutic market across the seven major countries in the
world was estimated at 1bn in 2003 with new technologies expected to be the
driver behind significant growth.

The proposed medical food contains a patented natural source of soluble fibre
extracted from the plantain. If successful, it will be the first medical food
which involves treatment of the actual inflammation associated with the disease,
unlike existing medical food treatments which only address nutrient
insufficiencies and imbalances in IBD sufferers.

Provexis had previously secured financial support for this project from the DTI
in 2004 with a 45,000 DTI SMART Feasibility Award.

The award from the North West Development Agency was won following a competitive
pitch which involved rigorous analysis of the Company's technology, intellectual
property and commercial capability by a team of independent referees.

Commenting on the grant, Provexis' Chief Executive, Dr Stephen Franklin, said:
'We are delighted to receive this substantial grant from the North West
Development Agency. Given the strength of the competition in bidding for this
award, it is a clear testament to the quality of the technology we are
developing, the robustness of the intellectual property and the scale of the
commercial opportunity. Crohn's Disease remains an area of significant unmet
clinical need in a therapeutic market that now exceeds 1bn. This grant enables
us to extend the scale of the clinical trial which commences next year.'